Gene editing is the suite of molecular tools that allows scientists to make precise changes to DNA inside living cells. From the revolutionary CRISPR-Cas9 system that acts as molecular scissors to newer techniques like base editing and prime editing that rewrite individual letters without cutting the double helix, these technologies are transforming medicine, agriculture, and fundamental biology. With the first CRISPR therapy (Casgevy) now FDA-approved and dozens of clinical trials underway, gene editing has moved from laboratory curiosity to clinical reality.
The foundational gene editing system using guide RNA and Cas9 protein to cut DNA at precise locations
Chemically converting one DNA base to another without cutting the double helix
Search-and-replace editing that can make all 12 point mutations plus small insertions and deletions
Modifying gene expression without altering the DNA sequence using dCas9 fused to epigenetic enzymes
Altering RNA molecules after transcription for reversible gene modification
CRISPR-based systems that bias inheritance to spread modifications through wild populations
SHERLOCK, DETECTR, and other CRISPR-based tools for rapid disease detection
In-depth analysis and expert-level coverage
Anti-CRISPR proteins (Acrs) are bacteriophage-encoded off-switches for CRISPR. Discover how Acrs work and why they are becoming essential safety tools.
Tirzepatide delivers 21% weight loss — at $1,000/month, forever. Could a single base-editing infusion ever replace the injection entirely?
Bridge RNAs are the June 2024 gene editing breakthrough beyond CRISPR — a single enzyme that can insert, delete, or invert DNA precisely. A complete guide.
Cas12a (Cpf1) is the smaller, sharper alternative to Cas9 — single-RNA, sticky-end cuts, AT-rich PAM. Learn how Cas12 enzymes power both editing and diagnostics.
Cas13 RNA editing targets RNA instead of DNA — enabling reversible knockdown, programmable RNA edits, and the SHERLOCK diagnostics platform. A complete guide.
Compact CRISPR editors like CasX, CasMINI, CasΦ, and Cas-CLOVER solve the AAV packaging limit and unlock new in vivo therapies.
CRISPR activation (CRISPRa) turns endogenous genes on without inserting transgenes. Learn how dCas9-VP64, SAM, SunTag, and VPR work — and where CRISPRa is heading clinically.
CRISPR interference (CRISPRi) silences genes without cutting DNA. Learn how dCas9-KRAB works, its key papers, and why it is reshaping therapeutics.
The 2026 longevity stack combines senolytics, peptides, and partial reprogramming into one framework. See which interventions have clinical evidence and how they layer.
Peptides and CRISPR are converging on the same disease targets, sharing delivery infrastructure, and increasingly working together inside single therapeutic programs.
Retron gene editing uses bacterial reverse transcriptases to generate single-stranded DNA inside cells — a clever solution to prime editing's template delivery problem.
Twin prime editing and PASTE extend prime editing to kilobase-scale insertions — using paired pegRNAs and serine integrases for full gene replacement.
Prime editing can rewrite DNA with surgical precision — no double-strand breaks, no bystander mutations, no RNA off-targets. From PE1 to PE7, from the lab to the NEJM, here is the definitive guide to the most versatile gene editing tool ever created.
A detailed comparison of CRISPR-Cas9, base editing, and prime editing — how each works, their strengths and limitations, and when to use which approach.
An in-depth look at how CRISPR components are delivered into cells, from viral vectors and lipid nanoparticles to electroporation and next-generation virus-like particles.
How CRISPR-edited stem cells, iPSC-derived therapies, and gene-edited organoids are creating a new paradigm in regenerative medicine — from FDA-approved therapies to experimental longevity treatments.
For the first time, multiple clinical trials are proving that CRISPR can safely edit genes inside the living human body. From Intellia's liver therapies to YolTech's kidney disease treatment, in vivo gene editing is no longer theoretical — it's working in patients.
How programmable RNA editing using ADAR enzymes offers a reversible, potentially safer alternative to permanent DNA modifications, and where the field stands today.
What if a single injection could permanently lower your cholesterol — no more daily statins? Verve Therapeutics and CRISPR Therapeutics are making this a reality with gene editing for cardiovascular disease.
How artificial intelligence is transforming gene editing, from designing better guide RNAs to predicting protein structures and engineering novel gene editors.
Casgevy was approved in December 2023 as a cure for sickle cell disease. Two years later, only ~165 patients have been treated. Here's why — and what's being done about it.
What if a gene therapy could be designed for just one patient? N-of-1 personalized gene therapies are making this a reality — and the FDA just created a new pathway to approve them.
RNA editing is having its breakout year. From Wave Life Sciences' endogenous ADAR platform to adaptamers that create programmable gene switches, 2026 marks the moment RNA editing moved from niche to mainstream.
DNA editing is permanent. RNA editing is reversible. Both can treat disease. Here's why reversibility might be the safer path for many genetic conditions.
Current CAR-T therapies cost $400K+, take weeks to manufacture, and require each patient's own cells. Gene-edited 'off-the-shelf' CAR-T could treat any patient instantly — if scientists can solve the persistence problem.
Cas9 is too big to fit inside AAV vectors for in vivo delivery. A new generation of compact CRISPR editors — from Cas12f achieving 90% efficiency to Cas3's clean deletion system — is solving the delivery problem that has held gene therapy back.
AI is transforming gene editing — from designing better guide RNAs to engineering entirely new CRISPR proteins. Here's how the convergence of AI and CRISPR is accelerating genetic medicine.
Excision BioTherapeutics is using CRISPR to cut HIV DNA out of infected cells — the first gene editing approach that could truly cure, not just manage, HIV/AIDS.
A new wave of CRISPR-based tools can turn genes on or off by editing chemical tags on DNA — without making a single cut. In 2026, epigenetic editing is emerging as a safer, reversible alternative to permanent genome surgery.
In 2018, He Jiankui created the world's first gene-edited babies. The scientific community condemned it. But the questions he raised — about enhancement, equity, and consent — haven't gone away.
Beta-thalassemia patients need blood transfusions every 2-4 weeks for life. Gene therapy is changing that — with Casgevy and Zynteglo already approved, and next-gen approaches in development.
Gene editing is transforming cancer treatment — from CRISPR-enhanced CAR-T cells that achieved 82% remission in leukemia to in vivo approaches that reprogram immune cells directly inside the body. Here's the complete landscape.
97% of patients attack-free for 3+ years from a single IV infusion. Intellia's lonvo-z could be the first in vivo CRISPR therapy approved — transforming gene editing from a transplant procedure into a simple injection.
CRISPR Therapeutics is engineering gene-edited stem cells that produce insulin without triggering immune rejection — potentially ending the need for daily injections for 8.7 million people with Type 1 diabetes.
The battle over CRISPR patents between the Broad Institute and UC Berkeley is one of the most consequential IP fights in biotech history. Here's who won, what it means, and why it matters.
70,000 people worldwide live with cystic fibrosis. Trikafta transformed treatment, but it's not a cure and doesn't work for everyone. Gene editing could change that — with prime editing achieving 58% correction of the F508del mutation in lung cells.
CRISPR isn't just for editing genes — it's becoming the fastest, cheapest way to detect diseases. From COVID to cancer, here's how SHERLOCK and DETECTR work.
APOE4 is the strongest genetic risk factor for Alzheimer's. What if we could edit it to the protective APOE2 variant? Researchers are working on exactly that — and the early results are promising.
Two gene therapies for sickle cell disease were approved on the same day. One uses CRISPR. The other uses gene addition. Here's how Casgevy and Lyfgenia compare — and why one company is failing.
The eye is the ideal organ for gene editing — immune-privileged, accessible, and small. From Luxturna to in vivo CRISPR, here's how gene editing is restoring vision.
Off-target editing is the biggest safety concern in gene editing. Here's how scientists detect it, measure it, and engineer around it — from high-fidelity Cas9 to prime editing's dual-check mechanism.
The same lipid nanoparticle technology that delivered COVID vaccines to billions is now delivering CRISPR to edit genes inside the body. Here's how the pandemic accelerated gene editing by a decade.
In 2024, surgeons transplanted gene-edited pig kidneys into living humans for the first time. With 100,000 Americans on the organ waitlist, CRISPR-edited pigs could end the transplant shortage.
What if you could silence a disease-causing gene without changing a single letter of DNA? Epigenetic editing does exactly that — and Tune Therapeutics just brought it to human clinical trials.
A single IV infusion of Verve's VERVE-102 reduced LDL cholesterol by up to 69% in patients with familial hypercholesterolemia — with zero serious adverse events. Base editing may offer a one-and-done cure for heart disease.
Prime Medicine's PM359 became the first prime editing therapy ever tested in a human patient — and the results exceeded expectations. Here's what happened, why it matters, and what comes next.
Accessible introductions for newcomers
Vertex Pharmaceuticals is pushing to expand Casgevy, the first approved CRISPR gene therapy, to children ages 5-11 with sickle cell disease. Here is why treating younger patients could prevent a lifetime of organ damage — and the challenges that come with it.
CRISPR cuts DNA like molecular scissors. Epigenetic editing flips genes on or off like a dimmer switch — no cuts required. Here is how the two approaches compare in 2026, and why the future likely needs both.
A comprehensive introduction to CRISPR-Cas9 gene editing, covering its discovery, molecular mechanism, real-world applications, and the ethical questions it raises.
Base editing offers a refined approach to gene editing that avoids cutting the DNA double helix entirely — like using a pencil eraser to fix a single typo instead of cutting a page in half.
How Casgevy became the first CRISPR-based gene therapy to win FDA approval, offering a potential cure for sickle cell disease.
From disease-resistant cattle to pig organs for human transplants to de-extinction of the woolly mammoth — CRISPR is reshaping our relationship with animals.
Gene-edited crops are entering the food supply worldwide. Here is how CRISPR agriculture differs from traditional GMOs, which products are already on the market, and why regulation varies so dramatically between countries.
Over 250 gene editing clinical trials are recruiting worldwide. Here's how to find them, understand eligibility, and what to expect if you enroll.
Gene-edited tomatoes, soybeans, and lettuce are already on store shelves. Are they different from GMOs? Are they safe? Here's what the science says.
The most common question about CRISPR: is it safe? Here's what clinical trial data, FDA reviews, and peer-reviewed research actually show about the risks and side effects of gene editing in humans.
Gene editing and gene therapy are turning 'incurable' genetic diseases into treatable — and even curable — conditions. Here are 10 diseases closest to a permanent cure.
GLP-1 drugs like Ozempic cost $1,000/month and require lifelong injections. What if a single gene edit could achieve the same effect permanently? Scientists are working on it.
Gene editing and gene therapy sound similar but work in fundamentally different ways. One adds a new gene copy. The other fixes the existing DNA. Here's the difference — and why it matters for patients.
How your cells read DNA instructions and build proteins — the process that gene editing ultimately aims to control.
A beginner-friendly guide to DNA — what it is, how it stores genetic information, and why it matters for gene editing.
Company analysis, trends, and investment insights
Watch CRISPR-Cas9 in action — from guide RNA targeting to DNA cutting and repair. An interactive visual guide to the world's most powerful gene editing tool.
Beginner · 3 minWatch base editing fix a single DNA letter without ever cutting the double helix — the pencil eraser of gene editing, explained visually.
Intermediate · 3 minWatch prime editing rewrite DNA with surgical precision — the 'search-and-replace' editor that writes new genetic sequences without cutting both strands.
Advanced · 4 minStart from DNA basics and build up to understanding CRISPR, base editing, prime editing, and delivery systems.
5 lessons · ~35 minMeet the scientists who made gene editing possible — from the discovery of CRISPR in salt marshes to Nobel Prizes and billion-dollar breakthroughs.
7 lessons · ~42 minAdenine Base Editor — a base editing tool that converts A-T base pairs to G-C. Uses an evolved adenosine deaminase fused to nickase Cas9. Together with CBEs, ABEs can correct roughly 60% of disease-causing point mutations.
Adenosine Deaminase Acting on RNA — a natural enzyme that converts adenosine (A) to inosine (I) in RNA, which the cell reads as guanosine (G). Harnessed for programmable RNA editing without altering DNA.
ABE — a base editor that converts A-T base pairs to G-C without double-strand breaks, using an engineered adenosine deaminase fused to nickase Cas9. Developed by the Liu lab (Gaudelli 2017 Nature). Used in Beam Therapeutics programs.
Natural phage-derived proteins (Acrs) that inhibit CRISPR-Cas systems, first described by Bondy-Denomy in 2013. Used as off-switches in therapeutic editing to limit off-target activity after on-target editing completes.
A precision gene editing technique that chemically converts one DNA base into another without cutting the double helix. Can correct ~60% of known disease-causing point mutations.
A programmable RNA that directs DNA recombination, discovered in 2024 by Patrick Hsu's group at the Arc Institute (Durrant et al. Nature). Enables insertions, deletions, and inversions via IS110 insertion sequences without double-strand breaks.
A CRISPR-associated protein (also called Cpf1) that cuts DNA using a single guide RNA. Unlike Cas9, Cas12a creates staggered cuts and recognizes T-rich PAM sequences, expanding the range of targetable sites.
Also called Cpf1 — a compact CRISPR nuclease discovered by Zhang lab in 2015. Uses a T-rich PAM, requires only a single RNA guide, and creates sticky-end cuts. Powers SHERLOCK and DETECTR diagnostics.
A CRISPR protein that targets and cuts RNA instead of DNA. Used for RNA knockdown, diagnostics (SHERLOCK), and RNA editing applications without permanently altering the genome.
An RNA-targeting CRISPR nuclease discovered in 2016 by Abudayyeh and Zhang. Cleaves RNA instead of DNA, enables reversible knockdown, and supports SHERLOCK diagnostics via collateral activity.
The molecular 'scissors' protein used in CRISPR gene editing. Cas9 cuts both strands of DNA at the location specified by the guide RNA.
An engineered, ultra-compact Cas protein roughly half the size of Cas9. Its small size makes it especially attractive for AAV-based delivery, where cargo capacity is limited to ~4.7 kb.
A compact CRISPR protein discovered in groundwater bacteria. Smaller than Cas9, making it easier to package in AAV vectors for gene therapy delivery. Licensed by Scribe Therapeutics.
Cytosine Base Editor — a base editing tool that converts C-G base pairs to T-A without cutting the DNA. Combines a nickase Cas9 with a cytidine deaminase enzyme. Developed by David Liu's lab.
Clustered Regularly Interspaced Short Palindromic Repeats — a natural bacterial immune system repurposed as a precise gene editing tool. Uses a guide RNA to direct the Cas9 protein to cut DNA at specific locations.
| Therapy | Company | Disease | Phase | Status |
|---|---|---|---|---|
| Casgevy (exagamglogene autotemcel) | CRISPR Therapeutics / Vertex Pharmaceuticals | Sickle cell disease & transfusion-dependent beta-thalassemia | Approved | Approved |
| NTLA-2001 | Intellia Therapeutics | Transthyretin (ATTR) amyloidosis | Phase 3 | Active |
| NTLA-2002 | Intellia Therapeutics | Hereditary angioedema (HAE) | Phase 2 | Active |
| BEAM-101 | Beam Therapeutics | Sickle cell disease | Phase 1/2 | Active |
| BEAM-302 | Beam Therapeutics | Alpha-1 antitrypsin deficiency (AATD) | Phase 1/2 | Active |
| BEAM-301 | Beam Therapeutics | Glycogen storage disease type 1a (GSD1a) | Phase 1/2 | Active |
| VERVE-101 | Verve Therapeutics | Heterozygous familial hypercholesterolemia (HeFH) | Phase 1 | Active |
| VERVE-201 | Verve Therapeutics | Cardiovascular disease (ANGPTL3 target) | Phase 1 | Active |
| CTX110 | CRISPR Therapeutics | Relapsed/refractory B-cell malignancies | Phase 1/2 | Active |
| CTX130 | CRISPR Therapeutics | T-cell malignancies and solid tumors | Phase 1/2 | Active |
